Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Ima Evaluations LLC

Neither a doctor nor a teaching hospital

Research payments

$7,675,757

2,029 payments

Through program year 2025, Ima Evaluations LLC is reported as receiving $7,675,757 in research payments, across 2,029 payments.

By program year

4 rows
Year Kind Amount Payments
2025 Research $828,116 389
2024 Research $4,846,639 523
2023 Research $1,623,350 1,100
2022 Research $377,653 17

Breakdown

Who paid Research payments · program years 2022–2025
  1. Moderna TX, Inc. $5,045,545 1,167 payments
  2. Pfizer Inc. $576,188 50 payments
  3. Regeneron Pharmaceuticals, Inc. $513,655 180 payments
  4. Seqirus USA Inc $379,924 310 payments
  5. AbbVie, Inc. $304,686 110 payments
  6. Sumitomo Pharma America, Inc. $284,258 59 payments
  7. Bavarian Nordic A/S $243,441 49 payments
  8. Chiesi USA, Inc. $125,012 24 payments
  9. Janssen Research & Development, LLC $70,100 15 payments
  10. Braintree Laboratories, Inc. $66,754 25 payments
Studies the money was for Research payments · program years 2022–2025
  1. A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age $2,733,999 47 payments
  2. A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 $1,490,470 1,031 payments
  3. A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Mrna-1403, A Multivalent Candidate Vaccine to Prevent Norovirus Acute Gastroenteritis in Adults 18 Years of Age $552,959 34 payments
  4. A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity $446,548 162 payments
  5. An Interventional Randomized Activecontrolled Phase 23 Study to Investigate the Safety Tolerability and Immunogenicity of Bivalent Bnt162b Rnabased Vaccine Candidates As A Booster Dose in Covid19 Vaccineexperienced Healthy Individuals $356,175 20 payments
  6. The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older $347,645 269 payments
  7. A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age $151,077 43 payments
  8. A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age $148,094 26 payments
  9. A Phase 1 Randomized Openlabel Trial to Evaluate the Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age $146,662 7 payments
  10. A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia $142,201 65 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record